Sotorasib, for non-small cell lung carcinoma (NSCLC) patients, was also the first targeted drug for treating Kristen Rat Sarcoma Viral oncogene homolog (KRAS) gene mutation [105]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.